By Brian Finrow and Jim Roberts
Today, Lumen announced significant new federal funding covering a Phase 2 clinical trial of our Covid-19 product, LMN-301. It is, we believe, the world’s first clinical program directed specifically at the GI manifestations of Covid-19. Like everything Lumen Bio does, LMN-301 is unique!
We’ve written about LMN-301’s rationale before, but given the lack of awareness of this subject, this piece is significantly longer than our usual Medium posts. We’ve also included more references for those interested in exploring the primary literature directly.
